ERIS - Eesti teadus- ja arendustegevuse infosüsteem

Elulookirjeldus (CV)
1.	Eesnimi	Alan
2.	Perekonnanimi	Altraja
3.	Töökoht	1) Tartu Ülikooli Kopsukliinik, Pulmonoloogia õppetool 2) Sihtasutus Tartu Ülikooli Kliinikum, Kopsukliinik
4.	Ametikoht	1) dotsent, kliiniku juhataja, õppetooli hoidja, alates 01.09.2005 pulmonoloogia korraline professor 2) arst-õppejõud
5.	Sünniaeg	31.12.1965 (päev.kuu.aasta)
6.	Haridus	Kõrgem 1) Tartu Ülikooli Arstiteaduskond, ravi eriala; lõpetanud 25.06.1990 2) Üldarsti kutse 25.06.1990 3) Arst-terapeudi kvalifikatsioon 06.1991 4) Kopsuarsti kvalifikatsioon 28.08.1999 5) Meditsiinidoktor (PhD) 12.10.1999
7.	Teenistuskäik	1) Tartu Ülikooli Kopsukliinik, internatuur: 1990-1991 2) Tartu Ülikooli Kopsukliinik, ordinaator: 1991- 1992 3) Doktorantuur pulmonoloogia erialal Tartu Ülikoolis: 1992-1996 4) Doktorantuur pulmonoloogia erialal Helsinki Ülikoolis: 10.1994-04.1999 5) Tartu Ülikooli Kopsukliinik, residentuur pulmonoloogia erialal: 01.10.1996-27.08.1999 6) Tartu Ülikooli Kopsukliinik, vanemassistent: 01.02.1999-31.08.2000 7) Tartu Ülikooli Kopsukliinik, dotsent: alates 01.09.2000 kuni 31.08.2005 8) Pulmonoloogia korraline professor alates 01.09.2005 9) SA TÜ Kliinikumi Kopsukliiniku juhataja 01.09.1999-31.01.2003
8.	Teaduskraad	PhD (meditsiin)
9.	Teaduskraadi välja andnud asutus, aasta	Helsinki Ülikool, arstiteaduskond, 1999.
10.	Tunnustused	1) 1. koht posterite konkursil Põhjamaade Kopsuarstide Kongressil Bergenis 1994 2) 1. koht väitekirjade teaduskliku konkursil Helsinki Ülikoolis 1999
11.	Teadusorganisatsiooniline ja –administratiivne tegevus	1) "The International Union Against Tuberculosis and Lung Diseases" liige alates aastast 1994 2) Eesti Kopsuarstide Seltsi liige alates aastast 1995 3) Eesti Kopsuarstide Seltsi juhatuse liige alates 30.05.2001 4) Euroopa Kopsuarstide Assotsiatsiooni ("The European Respiratory Society") liige alates 01.01.2000 5) Euroopa Kopsuarstide Assotsiatsiooni ("The European Respiratory Society") nõukogu liige alates 11.12.2000 ja Eesti Rahvuslik delegaat 11.12.2000-08.09.2004 6) Euroopa Kopsuarstide Seltsi ("The European Respiratory Society") nominatsioonikomitee liige 01.10.2003-31.12.2004 7) Tartu Ülikooli Kopsukliiniku Pulmonoloogia Õppetooli juhataja 14.06.1999 8) Pulmonoloogia eriala residentuuri üldjuhendaja alates 01.09.1999 9) Tartu Ülikooli Arstiteaduskonna Nõukogu liige alates 1999/2000 õppeaastast 10) Tartu Ülikooli Kopsukliiniku juhataja alates 01.09.1999 11) Eesti Vabariigi Sotsiaalministeeriumi pulmonoloogia erialakomisjoni liige alates 29.11.2000 12) SA Tartu Ülikooli Kliinikum, Kopsukliiniku juhataja 07.09.1999-31.01.2003 13) Eesti Riikliku Tuberkuloositõrje programmi nõukogu liige 12.01.2001-31.03.2002 14) Tartu Ülikooli Arstiteaduskonna õppekomisjoni liige alates 2001. a. 15) Tartu Ülikooli arstiteaduse ja farmaatsia doktoriõppe vastuvõtukomisjoni liige 16) Arstiteaduse lõpueksami ja üldarstieksami komisjoni esimees alates 10.03.2003
12.	Juhendamisel kaitstud väitekirjad	Martin Kadai, MSc, 2005, juh. Alan Altraja. "The effect of proinflammatory mediators on the expression of tenascin and laminin by bronchial epithelial cells with special respect to cysteinyl leukotrienes". Tartu Ülikool
13.	Teadustöö põhisuunad	1) Bronhiaalastma jt. põletikuliste kopsuhaiguste (krooniline obstruktiivne kopsuhaigus, bronhiektaasiatõbi jne.) patogenees, erilise rõhuasetusega ekstratsellulaarse maatriksi kahjustusele ja koe ümberehituslikele muutustele 2) Hingamisteede põletikuliste haiguste ravi hindamine rakulistele muutustele ja remodelleerumisele avaldatava efekti valguses 3) Oksüdatiivne stress ja muutused antioksüdantse potentsiaali erinevate elementide põletikulste kopsuhaiguste korral 4) Alumiste hingamisteede infektsioonide etioloogia, tekitajate iseloomustamine, antibakteriaalne farmakoteraapia ja ravimresistentsuse küsimused 5) Kopsutuberkuloosi analüütiline epidemioloogia ja ravi küsimused. Multiresistentne tuberkuloos, selle ravi võimalused 6) Multiresistentse tuberkuloosi ravi farmakoökonoomika ja ravitulemused erinevate ravistrateegiate ja raviskeemide rakendamisel, ravimresistentsuse lisandumine ravi ajal
14.	Jooksvad grandid	1) ETF grant nr. 5011: "Ekstratsellulaarse maatriksi proteiinide ekspressioon inimese hingamisteede struktuursetes rakkudes: oksüdatiivse stressi mõju ja põletikumediaatorite moduleeriv toime", 01.01.2002-31.12.2005, põhitäitja
15.	Teaduspublikatsioonid	Altraja S, Rekker E, Altraja A. Cysteinyl leukotrienes enhance expression of tenascin and laminin beta2 chain by human lung fibroblasts. Proc Am Thoracic Soc 2005; 2: A76. Laitinen A, Lindqvist A, Halme M, Altraja A, Laitinen LA. Leukotriene E4–induced persistent eosinophilia and airway obstruction are reversed by zafirlukast in patients with asthma. J Allergy Clin Immunol 2005; 115: 259-265. Pehme L, Hollo V, Rahu M, Altraja A. Tuberculosis during fundamental societal changes in Estonia with special respect reference to extrapulmonary manifestations. Chest 2005; 127(4): 1289-1295. Altraja A, Kadai M, Altraja S. Cysteinyl leukotrienes increase tenascin expression by human bronchial epithelial cells. Am J Respir Crit Care Med 2004; 169(Suppl.): A454. Altraja S, Kadai M, Altraja A. Oxidative stress in bronchial epithelial cells: relations to extracellular matrix synthesis. Eur Respir J 2004; 24(Suppl. 48): 106s. Altraja S, Kadai M, Altraja A. Leukotriene E4 increases tenascin production by human bronchial epithelial cells. Eur Respir J 2003; 22(Suppl. 45): 36s. Karjalainen E-M, Lindqvist A, Laitinen LA, Kava T, Altraja A, Halme M, Laitinen A. Airway inflammation and basement membrane tenascin in newly diagnosed atopic and nonatopic asthma. Respir Med 2003; 97: 1045-1051. Lindqvist A, Karjalainen E-M, Laitinen LA, Kava T, Altraja A, Pulkkinen M, Halme M, Laitinen A. Salmeterol resolves airway obstruction but does not possess anti-inflammatory efficacy in patients with newly diagnosed asthma. A randomized, double-blind, parallel group biopsy study comparing the effects of salmeterol, fluticasone propionate, and disodium cromoglycate. J Allergy Clin Immunol 2003; 112: 23-28. Karjalainen EM, Laitinen A, Sue-Chu M, Altraja A, Bjermer L, Laitinen LA. Evidence of airway inflammation and remodeling in ski athletes with and without bronchial hyperresponsiveness to methacholine. Am J Respir Crit Care Med 2000; 161: 2086-2091. Laitinen A, Karjalainen EM, Altraja A, Laitinen LA. Histopathologic features of early and progressive asthma. J Allergy Clin Immunol 2000; 105(Suppl.): 509-513. Laitinen LA, Altraja A, Karjalainen EM, Laitinen A. Early interventions in asthma with inhaled corticosteroids. J Allergy Clin Immunol 2000; 105(Suppl.): 582-585. Altraja A, Laitinen A, Meriste S, Marran S, Märtson T, Sillastu H, Laitinen LA. Regular albuterol or nedocromil sodium - effects on airway subepithelial tenascin in asthma. Respir Med 1999; 93: 445-453. Sue-Chu M, Karjalainen EM, Altraja A, Laitinen A, Laitinen LA, Næess AB, Larsson L, Bjermer L. Lymphoid aggregates in endobronchial biopsies from young elite cross-country skiers. Am J Respir Crit Care Med 1998; 158: 597-601. Laitinen A, Altraja A, Kämpe M, Linden M, Virtanen I, Laitinen LA. Tenascin is increased in airway basement membrane of asthmatics and decreased by an inhaled steroid. Am J Respir Crit Care Med 1997; 156: 951-958. Altraja A, Laitinen A, Meriste S, Marran S, Märtson T, Sillastu H, Laitinen LA. Effect of regular nedocromil sodium or albuterol on bronchial inflammation in chronic asthma. J Allergy Clin Immunol 1996; 98(Suppl.): S58-S64. Altraja A, Laitinen A, Virtanen I, Kämpe M, Simonsson BG, Karlsson SE, Håkansson L, Venge P, Sillastu H, Laitinen LA. Expression of laminins in the airways in various types asthmatic patients: a morphometric study. Am J Respir Cell Mol Biol 1996; 15: 482-488. Laitinen LA, Laitinen A, Altraja A, Virtanen I, Kämpe M, Simonsson BG, Karlsson SE, Håkansson L, Venge P, Sillastu H. Bronchial biopsy findings in intermittent or “early” asthma. J Allergy Clin Immunol 1996; 98(Suppl.): S3-S6.

viimati muudetud: 06.08.2005

Curriculum Vitae (CV)
1.	First Name	Alan
2.	Surname	Altraja
3.	Institution	1) Tartu University Lung Clinic, Department of Pulmonary Medicine 2) Tartu University Clinics, Lung Clinic
4.	Position	1) Associate professor, Head of the Department of Pulmonary Medicine, from 01.09.2005, Professor of Pulmonary Medicine 2) Pulmonary physician
5.	Date of birth	31.12.1965 (day.month.year)
6.	Education	University Degree, Ph.D. 1) University of Tartu, Faculty of Medicine: Graduated 25.06.1990 2) Medical Doctor: 25.06.1990 3) Licensee on General Medicine: 06.1991 4) Pulmonary Physician: 28.08.1999 5) PhD (Medicine) 12.10.1999
7.	Research and professional experience	1) Tartu University Lung Clinic, physician- intern: 1990-1991 2) Tartu University Lung Clinic, pulmonary physician: 1991-1992 3) Candidate for the PhD Degree, University of Tartu: 1992-1996 4) Candidate for the PhD Degree, University of Helsinki: 10.1994-04.1999 5) Tartu University Lung Hospital, Resident in Pulmonary Medicine: 01.10.1996- 27.08.1999 6) Senior lecturer in Pulmonary Medicine, Tartu University Lung Clinic: 01.02.1999- 31.08.2000 7) Associate professor in Pulmonary Medicine, Tartu University Lung Clinic: 01.09.2000-31.08.2005 8) Professor of Pulmonary Medicine since 01.09.2005 9) Head of the Lung Clinic of the Tartu University Clinics: 01.09.1999-31.01.2003
8.	Academic degree	PhD (Medicine)
9.	Dates and sites of earning the degrees	12.10.1999, University of Helsinki, Faculty of Medicine
10.	Honours/awards	1) 1st prize in poster competition at the Nordic Congress on Pulmonary Medicine in Bergen, 1994 2) 1st prize in PhD thesis' scientific competition of Helsinki University in 1999
11.	Research-administrative experience	1) The International Union Against Tuberculosis and Lung Diseases, member since 1994 2) The Estonian Respiratory Society, member since 1995 3) The Estonian Respiratory Society, member of the Board since 30.05.2001 4) The European Respiratory Society, member since 01.01.2000 5) The European Respiratory Society, member of the Council ans national delegate for Estonia 11.12.2000-08.09.2004 6) The European respiratory Society, member of the Nomination Committee 01.10.2003-31.12.2004 7) Head of the Department of Pulmonary Medicine, Tartu University Lung Clinic since 14.06.1999 8) General supervisor of the residentship on pulmonary medicine since 01.09.1999 9) Member of the Council of the Faculty of Medicine, University of Tartu since 1999 10) Head of the Tartu University Lung Clinic since 01.09.1999 11) Member of the Commission of Pulmonary Medicine at the Ministry of Social Affairs of Estonia since 29.11.2000 12) Head of the Lung Clinic of the Tartu University Clinics 07.09.1999-31.01.2003 13) Member of the Council of the State Program of Tuberculosis Control 12.01.2001-31.03.2002 14) Member of the teaching commission at the Faculty of Medicine, University of Tartu from 2001 15) Member of the Admissions Committee for Ph.D. students in Medicine and Pharmacy at the University of Tartu 16) Chairman of the commission of the final examination in medicine (from 10.03.2003)
12.	Supervised dissertations	Martin Kadai, MSc, 2005, superv. Alan Altraja. "The effect of proinflammatory mediators on the expression of tenascin and laminin by bronchial epithelial cells with special respect to cysteinyl leukotrienes". Tartu Ülikool
13.	Current research program	1) Pathogenesis of bronchial asthma etc. inflammatory lung diseases (chronic obstructive pulmonary disease, bronchiectasis etc.) with a special emphasis on extracellular matrix alterations and tissue remodeling 2) Assessment of the efficacy of anti- inflammatory treatment in the light of cellular pathology and tissue remodeling 3) Oxidative stress and changes in different elements of antioxidant capacity in inflammatory lung diseases 4) Etiology and characterization of pathogens causing community-acquired lower respiratory tract infections. Antibacterial therapy and issues of drug resistance 5) Analytical epidemiology of pulmonary tuberculosis. Multidrug-resistant tuberculosis, treatment options 6) Pharmacoeconomics and results of management of MDR-TB with application of different treatment strategies and drug schemes, addition of resistance to antituberculosis drugs during the treatment period
14.	Current grant funding	1) Grant no. 5011 from the Estonian Science Foundation: "Expression of Extracellular Matrix Proteins by Human Airway Structural Cells: the Effect of Oxidative Stress and Modulation by Inflammatory Mediators", 01.01.2002-31.12.2005, principal investigator
15.	List of most important publications	Altraja S, Rekker E, Altraja A. Cysteinyl leukotrienes enhance expression of tenascin and laminin beta2 chain by human lung fibroblasts. Proc Am Thoracic Soc 2005; 2: A76. Laitinen A, Lindqvist A, Halme M, Altraja A, Laitinen LA. Leukotriene E4–induced persistent eosinophilia and airway obstruction are reversed by zafirlukast in patients with asthma. J Allergy Clin Immunol 2005; 115: 259-265. Pehme L, Hollo V, Rahu M, Altraja A. Tuberculosis during fundamental societal changes in Estonia with special respect reference to extrapulmonary manifestations. Chest 2005; 127(4): 1289-1295. Altraja A, Kadai M, Altraja S. Cysteinyl leukotrienes increase tenascin expression by human bronchial epithelial cells. Am J Respir Crit Care Med 2004; 169(Suppl.): A454. Altraja S, Kadai M, Altraja A. Oxidative stress in bronchial epithelial cells: relations to extracellular matrix synthesis. Eur Respir J 2004; 24(Suppl. 48): 106s. Altraja S, Kadai M, Altraja A. Leukotriene E4 increases tenascin production by human bronchial epithelial cells. Eur Respir J 2003; 22(Suppl. 45): 36s. Karjalainen E-M, Lindqvist A, Laitinen LA, Kava T, Altraja A, Halme M, Laitinen A. Airway inflammation and basement membrane tenascin in newly diagnosed atopic and nonatopic asthma. Respir Med 2003; 97: 1045-1051. Lindqvist A, Karjalainen E-M, Laitinen LA, Kava T, Altraja A, Pulkkinen M, Halme M, Laitinen A. Salmeterol resolves airway obstruction but does not possess anti-inflammatory efficacy in patients with newly diagnosed asthma. A randomized, double-blind, parallel group biopsy study comparing the effects of salmeterol, fluticasone propionate, and disodium cromoglycate. J Allergy Clin Immunol 2003; 112: 23-28. Karjalainen EM, Laitinen A, Sue-Chu M, Altraja A, Bjermer L, Laitinen LA. Evidence of airway inflammation and remodeling in ski athletes with and without bronchial hyperresponsiveness to methacholine. Am J Respir Crit Care Med 2000; 161: 2086-2091. Laitinen A, Karjalainen EM, Altraja A, Laitinen LA. Histopathologic features of early and progressive asthma. J Allergy Clin Immunol 2000; 105(Suppl.): 509-513. Laitinen LA, Altraja A, Karjalainen EM, Laitinen A. Early interventions in asthma with inhaled corticosteroids. J Allergy Clin Immunol 2000; 105(Suppl.): 582-585. Altraja A, Laitinen A, Meriste S, Marran S, Märtson T, Sillastu H, Laitinen LA. Regular albuterol or nedocromil sodium - effects on airway subepithelial tenascin in asthma. Respir Med 1999; 93: 445-453. Sue-Chu M, Karjalainen EM, Altraja A, Laitinen A, Laitinen LA, Næess AB, Larsson L, Bjermer L. Lymphoid aggregates in endobronchial biopsies from young elite cross-country skiers. Am J Respir Crit Care Med 1998; 158: 597-601. Laitinen A, Altraja A, Kämpe M, Linden M, Virtanen I, Laitinen LA. Tenascin is increased in airway basement membrane of asthmatics and decreased by an inhaled steroid. Am J Respir Crit Care Med 1997; 156: 951-958. Altraja A, Laitinen A, Meriste S, Marran S, Märtson T, Sillastu H, Laitinen LA. Effect of regular nedocromil sodium or albuterol on bronchial inflammation in chronic asthma. J Allergy Clin Immunol 1996; 98(Suppl.): S58-S64. Altraja A, Laitinen A, Virtanen I, Kämpe M, Simonsson BG, Karlsson SE, Håkansson L, Venge P, Sillastu H, Laitinen LA. Expression of laminins in the airways in various types asthmatic patients: a morphometric study. Am J Respir Cell Mol Biol 1996; 15: 482-488. Laitinen LA, Laitinen A, Altraja A, Virtanen I, Kämpe M, Simonsson BG, Karlsson SE, Håkansson L, Venge P, Sillastu H. Bronchial biopsy findings in intermittent or “early” asthma. J Allergy Clin Immunol 1996; 98(Suppl.): S3-S6.

last updated: 06.08.2005